NLS Collaboration

Umeå based HiloProbe has entered a partnership with the major international company Biocartis Group. This is a strategically important step for HiloProbe in their aim to reach out globally with its colorectal cancer test-product, ColoNode, they state. “We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus […]

Salipro Biotech and DyNAbind have announced the achievement of a key milestone from their collaboration. The collaboration combines Salipro Biotech’s platform technology for membrane proteins with DyNAbind’s DNA-Encoded Library (DEL) technology to accelerate the development of novel drugs for challenging targets. Membrane proteins like GPCRs, SLC transporters and Ion Channels are an important but difficult-to-drug […]

Swedish Neogap and the Zurich-based company Cellerys has entered a collaboration related to Phase II study of a new therapy for multiple sclerosis. Cellerys will use Neogap’s patented EpiTCer technology in its upcoming Phase II study of a new type of cell therapy aimed at inducing antigen-specific immune tolerance in patients with multiple sclerosis (MS). […]

Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and it SeqImmune discovery module, which is a sequence-first workflow for early-on repertoire capture and generation of maximum initial diversity. Lundbeck has licensed Alloy’s ATX-Gx humanized transgenic mouse platform since 2020, and this partnership reflects a deepening of the relationship between the companies, […]

Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody […]

Aspect Biosystems and Novo Nordisk have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s […]